BLU 14.74 BELLUS Health Inc.
| Range: | 6.38-14.76 | Vol Avg: | 5381551 | Last Div: | 0 | Changes: | 0.01 |
| Beta: | -0.28 | Cap: | 1.87B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Oct 27 2000 | Empoloyees: | 74 | ||
| CUSIP: | 07987C204 | CIK: | 0001259942 | ISIN: | CA07987C2040 | Country: | CA |
| CEO: | Mr. Roberto Francesco Bellini | Website: | https://www.bellushealth.com | ||||
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow